Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OVAS's Cash to Debt is ranked higher than
73% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. OVAS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OVAS' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Equity to Asset 0.96
OVAS's Equity to Asset is ranked higher than
95% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OVAS: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
OVAS' s 10-Year Equity to Asset Range
Min: 0.96  Med: 0.96 Max: 0.96
Current: 0.96
Interest Coverage No Debt
OVAS's Interest Coverage is ranked lower than
59% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OVAS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 73.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -380640.00
OVAS's Operating margin (%) is ranked lower than
100% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. OVAS: -380640.00 )
Ranked among companies with meaningful Operating margin (%) only.
OVAS' s 10-Year Operating margin (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -380640
Net-margin (%) -392746.67
OVAS's Net-margin (%) is ranked lower than
99% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. OVAS: -392746.67 )
Ranked among companies with meaningful Net-margin (%) only.
OVAS' s 10-Year Net-margin (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -392746.67
ROE (%) -64.29
OVAS's ROE (%) is ranked lower than
70% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. OVAS: -64.29 )
Ranked among companies with meaningful ROE (%) only.
OVAS' s 10-Year ROE (%) Range
Min: -102.08  Med: -95.33 Max: -80.21
Current: -64.29
-102.08
-80.21
ROA (%) -59.22
OVAS's ROA (%) is ranked lower than
75% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. OVAS: -59.22 )
Ranked among companies with meaningful ROA (%) only.
OVAS' s 10-Year ROA (%) Range
Min: -87.56  Med: -72.29 Max: -72.25
Current: -59.22
-87.56
-72.25
ROC (Joel Greenblatt) (%) -2077.73
OVAS's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. OVAS: -2077.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OVAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3579.1  Med: -3561.61 Max: -2257.26
Current: -2077.73
-3579.1
-2257.26
» OVAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OVAS Guru Trades in

OVAS Guru Trades in

Q4 2014

OVAS Guru Trades in Q4 2014

Jim Simons 47,300 sh (New)
» More
Q1 2015

OVAS Guru Trades in Q1 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.82
OVAS's P/B is ranked lower than
52% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OVAS: 4.82 )
Ranked among companies with meaningful P/B only.
OVAS' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 23.6
Current: 4.82
0
23.6
Current Ratio 25.92
OVAS's Current Ratio is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. OVAS: 25.92 )
Ranked among companies with meaningful Current Ratio only.
OVAS' s 10-Year Current Ratio Range
Min: 6.08  Med: 16.96 Max: 30.5
Current: 25.92
6.08
30.5
Quick Ratio 25.92
OVAS's Quick Ratio is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OVAS: 25.92 )
Ranked among companies with meaningful Quick Ratio only.
OVAS' s 10-Year Quick Ratio Range
Min: 6.08  Med: 16.96 Max: 30.5
Current: 25.92
6.08
30.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.99
OVAS's Price/Net Cash is ranked higher than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. OVAS: 4.99 )
Ranked among companies with meaningful Price/Net Cash only.
OVAS' s 10-Year Price/Net Cash Range
Min: 2.51  Med: 3.88 Max: 21.26
Current: 4.99
2.51
21.26
Price/Net Current Asset Value 4.93
OVAS's Price/Net Current Asset Value is ranked higher than
66% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. OVAS: 4.93 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OVAS' s 10-Year Price/Net Current Asset Value Range
Min: 2.5  Med: 3.81 Max: 20.66
Current: 4.93
2.5
20.66
Price/Tangible Book 4.80
OVAS's Price/Tangible Book is ranked higher than
56% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. OVAS: 4.80 )
Ranked among companies with meaningful Price/Tangible Book only.
OVAS' s 10-Year Price/Tangible Book Range
Min: 2.42  Med: 3.65 Max: 19.23
Current: 4.8
2.42
19.23
Earnings Yield (Greenblatt) (%) -8.82
OVAS's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. OVAS: -8.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OVAS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.68  Med: 0.00 Max: 0
Current: -8.82
-10.68
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3OS.Germany,
OvaScience, Inc. was established in 2011 & is based in Cambridge, Massachusetts. The Company is a life science company developing proprietary products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011.
» More Articles for OVAS

Headlines

Articles On GuruFocus.com
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Analyst Remains Bullish While OvaScience Posts Losses in Q4 Report Mar 18 2015 
OvaScience’s Fertility Treatment Shows Promise Jan 20 2015 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 

More From Other Websites
Strauss Law P.L.L.C. Announces Investigation of OvaScience, Inc. Jul 27 2015
​Short sellers retreat from Sarepta and OvaScience Jul 20 2015
How short sellers threaten innovations that could benefit patients Jul 06 2015
​Five Bay State biotech firms investors love to hate Jun 30 2015
Coverage initiated on OvaScience by JP Morgan Jun 29 2015
On the move: New hires and job transitions in the local life science industry Jun 23 2015
OvaScience to Present at the JMP Securities Life Sciences Conference Jun 18 2015
​Clinical data may not win over OvaScience skeptics — but revenue will Jun 17 2015
OvaScience’s AUGMENT Treatment Shows Improved Pregnancy Rates and Live Births in Women with Poor... Jun 17 2015
OVASCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 10 2015
OvaScience Expands Senior Team with Two New Key Hires Jun 05 2015
How a tiny cell component grew into Genzyme and 43 other biotechs Jun 05 2015
OvaScience Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors Jun 05 2015
OvaScience to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
OVASCIENCE, INC. Financials May 20 2015
OvaScience Announces Ravi Mehrotra, Ph.D., Joins as Chief Corporate Development Officer May 18 2015
OvaScience’s AUGMENT Fertility Treatment Continues to Demonstrate Improved Pregnancy Rates in... May 15 2015
OVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2015
OvaScience Reports First Quarter 2015 Financial Results May 11 2015
OvaScience, Inc. (OVAS) in Focus: Stock Jumps 5.1% - Tale of the Tape May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK